P582: FIRST RESULTS OF A PHASE II STUDY (STIMULUS-AML1) INVESTIGATING SABATOLIMAB + AZACITIDINE + VENETOCLAX IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA

• A. M. Zeidan,
• J. Westermann,
• T. Kovacsovics,
• S. Assouline,
• A. C. Schuh,
• H.-J. Kim,
• G. Rodriguez Macias,
• D. Sanford,
• M. R. Luskin,
• E. M. Stein,
• K. Malek,
• J. Lyu,
• M. Stegert,
• J. Esteve

Affiliations

A. M. Zeidan

1 Yale University and Yale Cancer Center, New Haven, United States of America

J. Westermann

2 Charité-University Medical Center Berlin, Campus Virchow Clinic, Berlin, Germany

T. Kovacsovics

3 University of Utah and Huntsman Cancer Institute, Salt Lake City, United States of America

S. Assouline

4 Jewish General Hospital, McGill University, Montreal

A. C. Schuh

5 Princess Margaret Cancer Centre, University of Toronto, Toronto, Canada

H.-J. Kim

6 Catholic Hematology Hospital, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea

G. Rodriguez Macias

7 Hospital General Universitario Gregorio Marañón, Madrid, Spain

D. Sanford

8 BC Cancer, University of British Columbia, Vancouver, Canada

M. R. Luskin

9 Dana-Farber Cancer Institute, Harvard Medical School, Boston

E. M. Stein

10 Memorial Sloan Kettering Cancer Center, New York, United States of America

K. Malek

11 Novartis Pharma AG, Basel, Switzerland

J. Lyu

12 Novartis Institutes for BioMedical Research, Shanghai, China

M. Stegert

11 Novartis Pharma AG, Basel, Switzerland

J. Esteve

13 Hospital Clínic, Barcelona, Spain